Moreover, the general inhibition of gp130 for cancer therapy has been intensively discussed, as a large number of different types of cancer exhibit aberrant production and response of IL-6-type cytokines that can trigger cell proliferation, differentiation, migration and invasion [Reviewed in (39)]. This evidence concerns the gene IL6 and cancer.